Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs

Publié le 21 Septembre 2015
Mis à jour le 5 juillet 2019

Background: hepatitis C virus (HCV) seroprevalence remains high in people who inject drug (PWID) populations, often above 60%. Highly effective direct-acting antiviral (DAA) regimens (90% efficacy) are becoming available for HCV treatment. This therapeutic revolution raises the possibility of eliminating HCV from this population. However, for this, an effective cascade of care is required. Methods: in the context of the available DAA therapies, we used a dynamic individual-based model including a model of the PWID social network to simulate the impact of improved testing, linkage to care, and adherence to treatment, and of modified treatment recommendation on the transmission and on the morbidity of HCV in PWID in France. Results: under the current incidence and cascade of care, with treatment initiated at fibrosis stage eF2, the HCV prevalence decreased from 42.8% to 24.9% [95% confidence interval 24.8% 24.9%] after 10 years. Changing treatment initiation criteria to treat from F0 was the only intervention leading to a substantial additional decrease in the prevalence, which fell to 11.6% [11.6% 11.7%] at 10 years. Combining this change with improved testing, linkage to care, and adherence to treatment decreased HCV prevalence to 7.0% [7.0% 7.1%] at 10 years and avoided 15% [14%-17%] and 29% [28% 30%] of cirrhosis complications over 10 and 40 years respectively. Conclusion: major decreases in prevalent HCV infections occur only when treatment is initiated at early stages of fibrosis, suggesting that systematic treatment in PWID, where incidence remains high, would be beneficial. However, elimination within the 10 next years will be difficult to achieve using treatment alone, even with a highly improved cascade of care.

Auteur : Cousien A, Tran VC, Deuffic Burban S, Jauffret Roustide M, Dhersin JS, Yazdanpanah Y
Hepatology, 2015, p. 54 p.